S3F0.F SANTHERA PHARM.HD.SF 0,10

Healthcare Biotechnology Frankfurt Exchange
16.08 EUR
Close of Nov 12, 2026
11.08 20.20
Market cap
EUR 246M
P/E
-
P/B
6.57x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is S3F0.F undervalued?

Graham number

The Graham number of SANTHERA PHARM.HD.SF 0,10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SANTHERA PHARM.HD.SF 0,10 fundamental analysis

No fundamental analysis for SANTHERA PHARM.HD.SF 0,10 yet.

SANTHERA PHARM.HD.SF 0,10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SANTHERA PHARM.HD.SF 0,10

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Full company profile